NEW YORK, NY – August 21, 2008 – Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Swedish Medical Center in Englewood, Colorado, has joined Delcath’s Phase III clinical trial for the treatment of metastatic melanoma in the liver. Swedish Medical Center is the ninth center to join this multi-center trial testing the Company’s Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan.

Delcath and Swedish Medical Center have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Dr. Charles Nutting, an interventional radiologist specializing in minimally invasive cancer treatment, will serve as the Principal Investigator. Commenting on joining this trial, Dr. Nutting stated, “PHP offers a unique and highly promising treatment modality for patients suffering from melanoma that has metastasized to the liver. Regional liver-directed therapy has shown tremendous success for patients suffering from primary and metastatic disease, and PHP offers an approach to treatment of the entire liver which has previously been lacking. I look forward to being able to provide this treatment to my patients, and to working with the technology as the Company explores the possibility for expanded use of its System.”

On Swedish Medical Center joining this trial, Richard L. Taney, President and CEO of Delcath, stated, “Dr. Nutting is a welcome addition to this trial and we are excited to be working with him. Dr. Nutting has been a leader in the development and use of regional cancer treatment modalities for many years and brings great experience and valuable leadership to this trial. Located immediately Southwest of Denver, Colorado, Swedish Medical Center is ideally situated to allow Delcath’s PHP treatment to reach an important geographic region and will further advance our goal of completing enrollment of this trial in 2009.”

About Swedish Medical Center
Swedish Medical Center is an acute care hospital with 368 licensed beds located in the South Denver metro area in Englewood, Colorado, where it has been a proud member of the community for more than 100 years. The Mission of Swedish Medical Center is to provide compassionate, high-quality patient care that meets the caring and cost effective expectations of our patients, physicians, employees and volunteers, and to preserve and strengthen the Swedish tradition of community service. The Vision of Swedish Medical Center is to become the provider of choice of healthcare services for our community. We will differentiate ourselves in the community from other healthcare providers through our centers of excellence: Neurosciences, in collaboration with the Colorado Neurological Institute, Adult and Pediatric Trauma Services, Cardiology Services, Cancer Treatment Services, Advanced Radiology Capabilities, and Women's and Children's Services.

About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath’s novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient’s bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.